Biotechnology
Fangzhou Inc. and Bristol Myers Squibb China Join Forces on a Strategic Alliance to Advance Internet Healthcare
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Fangzhou Inc. ("Fangzhou" or the "Company") (06086.HK), a pioneer in Internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb ("BMS")China on December 16th. The partnership was officially formalized with the signing of a colla...
2024-12-19 12:40
1060
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
Highlights * Clarity has developed a proprietary fibroblast activation protein (FAP)-targeted radiopharmaceutical product that can be used with the perfect pairing of copper isotopes for the diagnosis and treatment of cancer. * The product, termed SAR-bisFAP, has shown strong tumour targeting...
2024-12-18 22:03
1391
Juncell Therapeutics Opens State-of-the-Art Facility for TIL Production
SHANGHAI, Dec. 18, 2024 /PRNewswire/ -- Shanghai Juncell Therapeutics Co., Ltd. (Juncell Therapeutics), a clinical-stage biotech focused on innovative IL-2-independent Tumor-Infiltrating Lymphocyte (TIL) therapies, announced the grand opening of its state-of-the-art TIL manufacturing facility loc...
2024-12-18 21:08
1236
Samsung invests in Generate: Biomedicines to advance AI-driven protein therapeutics discovery
- Samsung Life Science Fund invests in Generate:Biomedicines, a Flagship Pioneering company leading in AI-enabled protein therapeutics discovery and development - Investment highlights Samsung's dedication to advancing innovation and creating a robust ecosystem for AI-enabled therapeutic develop...
2024-12-18 13:09
1701
U.S. FDA approves Celltrion's STEQEYMA® (ustekinumab-stba), a biosimilar to STELARA® (ustekinumab)
* STEQEYMA (CT-P43) is approved for both adult and pediatric patients with plaque psoriasis (PsO) and active psoriatic arthritis (PsA) as well as adults with Crohn's disease (CD) and ulcerative colitis (UC) * STEQEYMA is a strategic addition to Celltrion's portfolio, expanding the portfolio a...
2024-12-18 11:50
905
Origin Agritech Holds Successful 2025 R&D and Business Management Conference
BEIJING, Dec. 17, 2024 /PRNewswire/ -- Origin Agritech Ltd. (NASDAQ: SEED) (the "Company" or "Origin"), a leading Chinese agricultural technology company, recently held its 2025 R&D and Business Management Conference inBeijing. The event brought together industry experts, including professors fro...
2024-12-17 21:00
1358
Great Bay Bio Completes First Close of Series B Financing
HONG KONG, Dec. 17, 2024 /PRNewswire/ -- Great Bay Bio (GBB) is thrilled to announce the successful first close of its Series B financing round. This milestone was achieved with the round led by a syndication of a well-known strategic investment institution and its affiliate, Tiger Jade Pebble A...
2024-12-17 16:42
1190
SK Biopharmaceuticals Inks Research Collaboration Agreement with ProEn Therapeutics Further Accelerating Expansion of Oncology Research and Pipeline for Global Competitiveness in Radiopharmaceuticals
SK Biopharmaceuticals, ProEn Therapeutics aim to advance up to 2 preclinical radiopharmaceutical candidates by 2027, via ArtBody™, a bivalent binder platform designed to selectively target tumor cells SK Biopharmaceuticals eyes innovative small protein-based radiopharmaceuticals on safety and ef...
2024-12-17 08:20
1129
Samsung Biologics listed among top most sustainable companies in Dow Jones Sustainability World Index
* Acknowledged for strong environmental, social, and governance (ESG) performance and continued commitment to sustainability through net-zero initiatives and responsible value chain management INCHEON, South Korea, Dec. 16, 2024 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a global contr...
2024-12-17 07:51
1237
Microbio Co., Ltd. (4128) Announces Promising Results of "MS-20" in Combination with Keytruda for Stage IIIb/IV Non-Small Cell Lung Cancer
CUPERTINO, Calif., Dec. 16, 2024 /PRNewswire/ -- Microbio Co., Ltd. (4128) today revealed encouraging results from an exploratory clinical trial of MS-20 combined with Keytruda (pembrolizumab) in stage IIIb/IV non-small cell lung cancer (NSCLC). The trial showed a threefold increase in the object...
2024-12-17 02:05
1062
Nona Biosciences Announces Discovery Collaboration with Candid Therapeutics for Next-Generation T-Cell Engagers
CAMBRIDGE, Mass., Dec. 16, 2024 /PRNewswire/ -- Nona Biosciences, a global biotechnology company providing a total solution from "Idea to IND" (I to ITM ), today announced a research collaboration and license agreement to discover next-generation T-cell engagers ("TCEs") with Candid Therapeutics, ...
2024-12-16 20:03
881
Young International Scientists Say: China-Myanmar Partnership Advances Agricultural Innovation
BEIJING, Dec. 13, 2024 /PRNewswire/ -- Mango, a tropical fruit rich in nutrients, has a vital position in Myanmar's agriculture.Myanmar researcher Nann Miky Moh Moh worked with Chinese scientists at Zhejiang University in east China on genetically improving the flavor and variety of the fruit. ...
2024-12-13 18:21
1194
Accropeutics Inc. Announces U.S. FDA Clearance of IND Application for RIPK2 Inhibitor AC-101
* Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerative Colitis (UC) * A Phase Ib Study of AC-101 for Ulcerative Colitis (UC) has been initiated in China * AC-101 demonstrated a favorable safety and PK/PD profile in healthy volunteers in Phase Ia ...
2024-12-13 12:57
1268
Transcenta Debuts Promising Anti-Tumor Activity of Novel LIV-1 Targeting ADCs with Site-Specific Conjugated Topo I Inhibitor Payload in TNBC Tumor Models at 2024 SABCS
PRINCETON, N.J. and SUZHOU, China, Dec. 12, 2024 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of antibody-based therapeutics, ann...
2024-12-13 08:00
1399
Bota Bio debuted the 2024 FiE and launched its subsidiary HeliaGenesis, focusing on food and nutrition industries
SAN FRANCISCO and HANGZHOU, China, Dec. 12, 2024 /PRNewswire/ -- The 31st Food Ingredients Europe (referred to as FiE) concluded successfully fromNovember 19th to 21st, 2024, in Frankfurt, Germany. The event brought together over 1,500 ingredient manufacturers and more than 25,000 professional bu...
2024-12-12 22:00
1595
CureGene Received Clinical Trial Approval in China for CG-0255 for Injection - A Novel Antiplatelet Therapy
SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- CureGene Pharmaceutical ("CureGene"), a biotechnology company dedicated to innovative treatments for critical unmet medical needs in cardio-cerebrovascular and antiviral disease, proudly announces the approval of its Clinical Trial Application by theChina's...
2024-12-12 21:00
1328
Porton Pharma Solutions and Aojin Life Sciences Announce Strategic Collaboration to Advance XDC Conjugate Drugs for Dual IND Filings in China and the U.S.
CHONGQING, China, Dec. 12, 2024 /PRNewswire/ -- Recently, Porton Pharma
Solutions Ltd. ("Porton") announced a strategic partnership with Aojin Life
Sciences (Yixing) Co., Ltd. ("Aojin Life Sciences").
2024-12-12 21:00
1414
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...
2024-12-12 21:00
1684
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
* Leading Green CRDMO Driven by Innovation for a Healthier Future * Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development, and Manufacturing Organizati...
2024-12-12 16:30
1426
KIND Presents Preclinical Results of AND017 in Animal Models of Sickle Cell Disease (SCD), Myelodysplastic Syndromes (MDS), and β-Thalassemia at the 66th American Society of Hematology Meeting and Exposition and Announces FDA Authorization of Investigational New Drug (IND) Application for AND017 for Clinical Trial in Sickle Cell Disease (SCD)
SAN FRANCISCO, Dec. 12, 2024 /PRNewswire/ -- Kind Pharmaceutical ("Hangzhou Andao Pharmaceutical Ltd. and Kind Pharmaceuticals LLC"), a clinical-stage biopharmaceutical company focused on developing innovative medicines to treat hematological diseases and cancers, today announced that preclinical...
2024-12-12 16:25
1254
Week's Top Stories
Most Reposted
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
[Picked up by 315 media titles]
2024-12-27 13:17
COCONEXT 2024 - FIRST EVER INTERNATIONAL COCONUT CONFERENCE HOLD IN VIETNAM
[Picked up by 298 media titles]
2024-12-31 14:18
Dahua Technology Obtains ISO 37301 Compliance Management System Certification
[Picked up by 280 media titles]
2024-12-30 15:33
Russell Reynolds Associates Appoints Euan Kenworthy as Singapore Country Manager
[Picked up by 273 media titles]
2025-01-02 08:16
CKGSB Professor Mei Jianping Launches Global Indices Tracking Impressionist, Contemporary, and Chinese Art Markets
[Picked up by 257 media titles]
2024-12-31 22:30Most Read
UTP LAUNCHES MALAYSIA'S FIRST BACHELOR IN INTEGRATED ENGINEERING PROGRAMME
2024-12-27 13:17
12740
Huawei Cloud Named a Challenger in Gartner® Magic Quadrant™ for Cloud DBMSs
2024-12-27 11:24
10835
/C O R R E C T I O N -- Ellington Properties/
2024-12-27 20:57
10085
Ascentage Pharma to Present at 43rd Annual J.P. Morgan Healthcare Conference
2024-12-27 09:44
8182